Lumigan contains the active ingredient bimatoprost. It is also known by the generic name bimatoprost ophthalmic solution. Lumigan is used to treat increased pressure in the eyes due to conditions like glaucoma or other eye diseases. This medication helps to prevent blindness by reducing eye pressure.
Lumigan pricing spectrum extends from £40.06 to £42.61 for each bottles. The key influencers are pack magnitude and the grade of active substances (1 or 10 ml).
Lumigan (generic name: bimatoprost) is an ophthalmic solution primarily utilized to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The medication works by increasing the outflow of aqueous humor, thereby lowering the pressure in the eye.
Lumigan belongs to the prostamide class of medications. Its mechanism of action involves mimicking the function of naturally occurring prostamides, which help to regulate intraocular pressure.
Lumigan is available as an ophthalmic solution in a 0.01% concentration. Commercially, it is supplied in multi-dose dropper bottles equipped with a safety seal to maintain sterility.
Lumigan is approved for the treatment of elevated intraocular pressure in patients diagnosed with open-angle glaucoma or ocular hypertension. It is not indicated for use in other types of glaucoma or other eye conditions.
Administer Lumigan once daily in the evening, directly into the affected eye. Ensure the dropper tip does not touch any surface, including the eye, to avoid contamination. Close the eye gently after application, avoiding blinking or squeezing to reduce systemic absorption.
Store Lumigan at a temperature between 2°C to 25°C (36°F to 77°F), protected from light. Ensure the bottle is tightly closed when not in use to prevent contamination. Do not freeze the medication.
The active ingredient, bimatoprost, selectively mimics prostamide activity, increasing the outflow of aqueous humor through the trabecular meshwork and uveoscleral routes, thereby reducing intraocular pressure.
Use in pediatric populations has not been established. In geriatric patients, no significant differences in safety or efficacy have been observed compared to younger adults. Caution is advised when used in nursing or pregnant women.
Common side effects include conjunctival hyperemia, ocular pruritus, and eyelid pigmentation. Long-term use may cause changes in eyelash number and growth, increased iris pigmentation, and potential vision blurriness.
Simultaneous use of Lumigan with other topical ophthalmic drugs requires administration of each drug at least five minutes apart. Beta-blockers, carbonic anhydrase inhibitors, and alpha agonists are often co-administered with Lumigan but require monitoring for cumulative effects.
Lumigan is contraindicated in patients with hypersensitivity to bimatoprost or any components of the formulation. Use caution in patients with active intraocular inflammation as the medication might exacerbate the condition.
If a dose is missed, it should be administered as soon as remembered. However, if it is almost time for the next dose, skip the missed dose and proceed with the next scheduled dose. Do not double the dose to make up for a missed one.
Do not dispose of Lumigan via wastewater or household waste. Consult a pharmacist for proper disposal methods, particularly for expired or no-longer-needed medication, to ensure environmental safety.
Regular ocular examination is essential to monitor intraocular pressure levels and assess therapeutic effectiveness. Periodic evaluation of the optic nerve and visual field testing may be recommended to monitor disease progression.
Instruct patients on the importance of adhering to the prescribed dosing schedule. Advise them to remove contact lenses before application and wait at least 15 minutes before reinsertion. Educate on potential side effects and the necessity of regular follow-up appointments.
Clinical trials have demonstrated a significant reduction in intraocular pressure levels with once-daily dosing of Lumigan, showing effective management over a 12-month period. Comparative studies indicate superior or comparable efficacy to other prostaglandin analogs.
Following ocular administration, bimatoprost is rapidly absorbed. Peak plasma concentrations occur within 10 minutes with elimination primarily through the kidneys. The systemic exposure is minimal with topical application.
Potential reversible changes in pigment may occur with Lumigan use, including increased brown pigmentation of the iris, periorbital tissue and eyelashes. Altered pigmentation changes often persist even after discontinuation of therapy.
Upon receipt, the bottle should remain sealed until ready for use. Once opened, Lumigan should be used within the recommended shelf life, taking into account the specific storage instructions to maintain drug efficacy and sterility.
In cases of suspected overdose, immediate ocular irrigation should be undertaken. Regular medical supervision is required to monitor potential systemic effects, though significant toxicity is rare with topical administration.